The Filing Desk

Shattuck Labs

STTK · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

STTK · Last close · November 13, 2026
$4.65
Value Shattuck Labs yourself

Shattuck Labs' revenue fell 82.5% to $1 million in fiscal 2025. Its operating margin was −5,150.8%, down from −1,408.3% a year earlier. Free cash flow was −$40 million. The diluted share count rose 37.1%.

Shattuck Labs, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001628280-26-014989 Updated
Revenue
$1M
82.5%
Operating margin
−5,150.8%
3742.5 pts
Net income
−$49M
 
Free cash flow
−$40M
 
Return on equity
−60.2%
7.0 pts
Market cap
$324M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Shattuck Labs does

Shattuck Labs is a clinical-stage biotechnology company with no approved products. It develops antibodies that block a protein called Death Receptor 3, or DR3, to treat inflammatory and immune-mediated diseases. Its lead drug candidate, SL-325, is designed to block the DR3/TL1A pathway more fully than antibodies that target TL1A, the molecule that switches DR3 on.

SL-325 is in a Phase 1 trial in healthy volunteers, and Shattuck Labs expects to start a Phase 2 trial in patients with Crohn's disease in the third quarter of 2026. Shattuck Labs also has bispecific antibodies and other candidates still in preclinical work.

It has no product revenue. Its plan is to move SL-325 through trials and, if they succeed, seek approval to sell it. It competes with other companies that have developed or are developing drugs for the same diseases, including TL1A-blocking antibodies. Its claims that SL-325 may work better than those drugs are the company's own beliefs, based on its early lab studies.

Its biggest risks, as it describes them

  • It needs more funding to finish developing its drugs, which could dilute shareholders.
  • It depends heavily on one lead candidate, SL-325, which is in early clinical development.
  • Trials may fail to show that its drugs are safe and work, or may be delayed by slow patient enrollment.
  • Competition from other companies developing drugs for the same diseases.
  • It has no approved products and has not completed any late-stage trial.
From Shattuck Labs's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Shattuck Labs lost money in fiscal 2025: a net loss of $49 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments2691611317378
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio11.7x7.4x12.5x8.9x11.7x
Quick ratio11.7x7.4x12.5x8.9x11.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Shattuck Labs' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Shattuck Labs reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−4,772.5%−813.5%−4,077.8%
Altman Z''5.51−7.23−3.77
Accruals ratio−3.3%−11.9%−9.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Shattuck Labs side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Shattuck LabsFY25−82.5%−5,150.8%−3,995.3%———
Inhibrx BiosciencesFY25550.0%−10,386.5%−9,986.5%——2Compare
Z SquaredFY25—−956.9%————Compare
Celldex TherapeuticsFY25−78.0%−18,599.8%−13,829.1%———Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1010301261
Revenue growth—0.5%202.2%−97.8%154.1%245.3%−82.5%
Gross profit———————
Research and development29385783746735
Operating income−25−37−45−103−92−81−52
Net income−24−37−45−102−87−75−49
Diluted EPS (US$)−3.17−2.36−1.07−2.41−2.05−1.49−0.70
Diluted shares (millions)8164242435170
Cash flow
Cash from operations−21−34−57−94−81−60−40
Capital expenditure01812000
Free cash flow−21−34−65−106−82−61−40
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation01667107
Balance sheet at fiscal year end
Cash and short-term investments393352691611317378
Debt incl. finance leases———————
Total assets453492992051609191
Total liabilities3039272915119
Shareholders' equity−343102721761458082
Margins and ratios
Gross margin———————
Operating margin−253.5%−371.8%−150.8%−15,848.0%−5,549.6%−1,408.3%−5,150.8%
Net margin−242.6%−368.5%−149.8%−15,635.7%−5,268.4%−1,318.1%−4,880.9%
Free cash flow margin−216.9%−346.1%−216.7%−16,274.9%−4,926.7%−1,058.8%−3,995.3%
Rule of 40 (growth + FCF margin)—−345.7%−14.5%−16,372.7%−4,772.5%−813.5%−4,077.8%
Return on capital———————
Return on equity—−26.6%−15.5%−45.5%−54.4%−67.2%−60.2%
Return on assets—−18.6%−13.9%−40.5%−47.9%−60.2%−53.6%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Shattuck Labs' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Shattuck Labs.